Clinical Report: Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity

Overview

This study evaluates surgical management patterns in breast cancer patients with BRCA1/2 pathogenic variants and variants of uncertain significance (VUS). It highlights the clinical implications of genetic testing results on surgical decision-making and the challenges posed by VUS.

Background

Breast cancer is the most prevalent cancer among women and a leading cause of cancer-related deaths globally. The identification of BRCA1/2 pathogenic variants significantly influences clinical management, including surgical options. However, the presence of VUS complicates decision-making, as their clinical significance remains uncertain, leading to potential overtreatment or inadequate management.

Data Highlights

Key Findings

• Pathogenic BRCA1/2 variants are associated with a significantly higher lifetime breast cancer risk (45%-75%) compared to the general population.
• VUS in BRCA1/2 present challenges in clinical decision-making, as their pathogenicity is often unclear.
• A total of 203 patients with BRCA variants or VUS were included in the final analysis after exclusions.
• Current guidelines recommend that clinical management decisions should not be based solely on the presence of a VUS.
• There is a need for expert genetic counseling to address the uncertainties surrounding VUS.

Clinical Implications

Clinicians should be aware of the significant impact that BRCA variant classification has on surgical decision-making in breast cancer patients. It is crucial to provide thorough genetic counseling to patients with VUS to mitigate potential overtreatment and ensure informed decision-making.

Conclusion

Understanding the implications of BRCA variant classification is essential for optimizing surgical management in breast cancer patients. Continued research and adherence to guidelines are necessary to navigate the complexities introduced by VUS.

References

1. The ASCO Post, 2024 -- ASCO and SSO Publish New Guideline on Germline Testing in Breast Cancer
2. The ASCO Post, 2021 -- Trends in Germline Genetic Testing in Women Diagnosed With Breast or Ovarian Cancer
3. The ASCO Post, 2015 -- Should Oncologists Be Ordering Breast Cancer Gene Panels?
4. The ASCO Post — With Genetic Discoveries, Breast Cancer Complexity Grows
5. The ASCO Post — Trends in Germline Genetic Testing in Women Diagnosed With Breast or Ovarian Cancer
6. ASCO and SSO Publish New Guideline on Germline Testing in Breast Cancer - The ASCO Post
7. Long-Term Oncologic Outcome of Breast-Conserving Treatment in Patients With Breast Cancer With BRCA Variants - PMC
8. Retrospective Analysis of the Uptake and Timing of Risk-Reducing Salpingo-Oophorectomy in Women With BRCA1/2 Pathogenic Variants - PMC